|
Pronunciation |
|
(soo
PROE
fen) |
|
|
U.S. Brand
Names |
|
Profenal®
Ophthalmic |
|
|
Generic
Available |
|
No |
|
|
Pharmacological Index |
|
Nonsteroidal Anti-Inflammatory Agent (NSAID) |
|
|
Use |
|
Inhibition of intraoperative miosis |
|
|
Pregnancy Risk
Factor |
|
C |
|
|
Contraindications |
|
Previous hypersensitivity or intolerance to suprofen; epithelial herpes
simplex keratitis; history of hypersensitivity reactions to aspirin or other
nonsteroidal anti-inflammatory agents |
|
|
Warnings/Precautions |
|
Use with caution in patients sensitive to acetylsalicylic acid and other
NSAIDs; some systemic absorption occurs; use with caution in patients with
bleeding tendencies; perform ophthalmic evaluation for those who develop eye
complaints during therapy (blurred vision, diminished vision, changes in color
vision, retinal changes) |
|
|
Adverse
Reactions |
|
1% to 10%: Topical: Transient burning or stinging, redness, iritis
<1%: Chemosis, photophobia, discomfort, pain, punctate epithelial staining
|
|
|
Overdosage/Toxicology |
|
Not usually a problem; if accidental oral ingestion, dilute with
fluids |
|
|
Drug
Interactions |
|
Decreased effect: When used concurrently with suprofen, acetylcholine
chloride and carbachol may be ineffective |
|
|
Mechanism of
Action |
|
Inhibits prostaglandin synthesis, acts on the hypothalamus heat-regulating
center to reduce fever, blocks prostaglandin synthetase action which prevents
formation of the platelet-aggregating substance thromboxane A2;
decreases pain receptor sensitivity. |
|
|
Pharmacodynamics/Kinetics |
|
Protein binding: 99%
Metabolism: Occurs in the liver to one major inactive metabolite
Half-life, elimination: 2-4 hours
Time to peak serum concentration: ~1 hour
Elimination: <15% excreted unchanged in urine in 48 hours
|
|
|
Usual Dosage |
|
Adults: On day of surgery, instill 2 drops in conjunctival sac at 3, 2, and 1
hour prior to surgery; or 2 drops in sac every 4 hours, while awake, the day
preceding surgery |
|
|
Mental Health: Effects
on Mental Status |
|
None reported |
|
|
Mental Health:
Effects on Psychiatric
Treatment |
|
None reported |
|
|
Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
No information available to require special precautions |
|
|
Dental Health:
Effects on Dental Treatment |
|
NSAID formulations are known to reversibly decrease platelet aggregation via
mechanisms different than observed with aspirin. The dentist should be aware of
the potential of abnormal coagulation. Caution should also be exercised in the
use of NSAIDs in patients already on anticoagulant therapy with drugs such as
warfarin (Coumadin®). |
|
|
Patient
Information |
|
Avoid aspirin and aspirin-containing products while taking this medication;
get instructions on administration of eye drops |
|
|
Nursing
Implications |
|
In elderly, remove contact lenses before administering; assess ability to
self-administer |
|
|
Dosage Forms |
|
Solution, ophthalmic: 1% (2.5 mL) |
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
|